IPLEDGE program (English Wikipedia)
Analysis of information sources in references of the Wikipedia article "IPLEDGE program" in English language version.
Last modified:
Ref.Un. Ref.Website
Global rank
English rank
low place
low place
low place
low place
1st place
1st place
4th place
4th place
1,078th place
916th place
15th place
8th place
low place
low place
low place
6,244th place
14th place
9th place
580th place
287th place
3,157th place
3,607th place
low place
low place
96th place
89th place
low place
low place
aadresources.org (Global: low place; English: low place)
email.aadresources.org
- "iPLEDGE issues are an unacceptable disruption to patient care" (Press release). American Academy of Dermatology Association.
adsabs.harvard.edu (Global: 14th place; English: 9th place)
ui.adsabs.harvard.edu
- Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3) e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210.
Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
biospace.com (Global: low place; English: 6,244th place)
- "FDA Fails To Postpone March 1 Start Date Of iPLEDGE Program For Isotretinoin Patients". BioSpace. February 21, 2006.
creativecommons.org (Global: 580th place; English: 287th place)
- Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3) e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
dermatologytimes.com (Global: low place; English: low place)
- "Managing acne female-to-male transgender persons". Dermatology Times. Retrieved 2021-03-20.
doi.org (Global: 2nd place; English: 2nd place)
- Layton A (May 2009). "The use of isotretinoin in acne". Dermato-Endocrinology. 1 (3): 162–9. doi:10.4161/derm.1.3.9364. PMC 2835909. PMID 20436884.
- Layton AM, Knaggs H, Taylor J, Cunliffe WJ (September 1993). "Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment". The British Journal of Dermatology. 129 (3): 292–6. doi:10.1111/j.1365-2133.1993.tb11849.x. PMID 8286227. S2CID 22251719.
- Thiboutot DM, Cockerell CJ (August 2006). "iPLEDGE: A Report from the Front Lines of Dermatologic Practice". The Virtual Mentor. 8 (8): 524–8. doi:10.1001/virtualmentor.2006.8.8.pfor1-0608. PMID 23234692.
- Sladden MJ, Harman KE (September 2007). "What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?". Archives of Dermatology. 143 (9): 1187–8. doi:10.1001/archderm.143.9.1187. PMID 17875883.
- Shin, Janet; Cheetham, T. Craig; Wong, Linda; Niu, Fang; Kass, Elizabeth; Yoshinaga, Monica A.; Sorel, Mike; McCombs, Jeffrey S.; Sidney, Stephen (December 2011). "The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system". Journal of the American Academy of Dermatology. 65 (6): 1117–1125. doi:10.1016/j.jaad.2010.09.017. PMID 21565419.
- Prevost N, English JC (October 2013). "Isotretinoin: update on controversial issues". Journal of Pediatric and Adolescent Gynecology. 26 (5): 290–3. doi:10.1016/j.jpag.2013.05.007. PMID 24147278.
- Robertson J, Polifka JE, Avner M, Chambers C, Delevan G, Koren G, Lavigne SV, Martinez LP, Miller RK, Carey JC (November 2005). "A survey of pregnant women using isotretinoin". Birth Defects Research. Part A, Clinical and Molecular Teratology. 73 (11): 881–7. doi:10.1002/bdra.20197. PMID 16228976.
Almost 1/4 of the women surveyed (24%; 8/34) did not recall having contraception counselling before starting their medications. Once therapy was initiated, 62% (21/34) recalled using a birth control method, but only 29% (6/21) recalled using 2 forms of birth control, as specified by the voluntary pregnancy prevention programs. Monthly pregnancy tests were not always conducted during treatment, as recalled by the surveyed women (56%; 19/34). As many as 24% (8/34) of the women surveyed recalled that they were not screened using 2 pregnancy tests before receiving a prescription, another recommendation of the programs. Only a small number of the women (30%; 6/20) in the United States recalled being enrolled in any manufacturers' voluntary pregnancy prevention survey. . . Results demonstrate that essential components of voluntary pregnancy prevention programs were not consistently followed, which resulted in fetal exposures.
- Kovitwanichkanont T, Driscoll T (September 2018). "A comparative review of the isotretinoin pregnancy risk management programs across four continents". International Journal of Dermatology. 57 (9): 1035–1046. doi:10.1111/ijd.13950. PMID 29508918. S2CID 3726217.
- Shah, Nidhi; Byrne, Morgan; Kirkorian, A. Yasmine (2021-09-01). "27483 Evaluating the economic burden of iPLEDGE on female patients". Journal of the American Academy of Dermatology. 85 (3): AB148. doi:10.1016/j.jaad.2021.06.606. ISSN 0190-9622.
- Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3) e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
- Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.
- Tirado Sánchez A, León Dorantes G (Nov–Dec 2005). "Erectile dysfunction during isotretinoin therapy". Actas Urologicas Espanolas. 29 (10): 974–6. doi:10.1016/s0210-4806(05)73379-9. PMID 16447596.
fda.gov (Global: 470th place; English: 329th place)
- "Drug Safety and Availability - Isotretinoin Capsule Information". Food and Drug Administration.[dead link]
- Research, Center for Drug Evaluation and (2021-10-12). "iPLEDGE Risk Evaluation and Mitigation Strategy (REMS)". FDA. Archived from the original on October 12, 2021.
- "FDA targets illegal online pharmacies in globally coordinated action". Food and Drug Administration. Archived from the original on 2017-02-17. Retrieved 2019-12-16.
- "RISK EVALUATION AND MITIGATION STRATEGY (REMS)". www.fda.gov. 2012. Archived from the original (PDF) on December 15, 2019. Retrieved 2019-07-03.
ipledgeprogram.com (Global: low place; English: low place)
- "iPledge REMS - Public Home Page". www.ipledgeprogram.com.
- "iPledge REMS - iPLEDGE Privacy Notice & Terms of Use". www.ipledgeprogram.com.
- "iPledge REMS - Public Home Page". www.ipledgeprogram.com.
isciii.es (Global: low place; English: low place)
scielo.isciii.es
- Tirado Sánchez A, León Dorantes G (Nov–Dec 2005). "Erectile dysfunction during isotretinoin therapy". Actas Urologicas Espanolas. 29 (10): 974–6. doi:10.1016/s0210-4806(05)73379-9. PMID 16447596.
jaad.org (Global: low place; English: low place)
- Shah, Nidhi; Byrne, Morgan; Kirkorian, A. Yasmine (2021-09-01). "27483 Evaluating the economic burden of iPLEDGE on female patients". Journal of the American Academy of Dermatology. 85 (3): AB148. doi:10.1016/j.jaad.2021.06.606. ISSN 0190-9622.
jamanetwork.com (Global: 3,157th place; English: 3,607th place)
- Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.
mdedge.com (Global: low place; English: low place)
- "iPLEDGE vexes dermatologists treating transgender patients". www.mdedge.com. Retrieved 2021-03-20.
medscape.com (Global: 1,078th place; English: 916th place)
- Darves, Bonnie (March 9, 2006). "Dermatologists Frustrated With Problematic iPledge Program". Medscape.
nih.gov (Global: 5th place; English: 5th place)
pubmed.ncbi.nlm.nih.gov
- Layton A (May 2009). "The use of isotretinoin in acne". Dermato-Endocrinology. 1 (3): 162–9. doi:10.4161/derm.1.3.9364. PMC 2835909. PMID 20436884.
- Layton AM, Knaggs H, Taylor J, Cunliffe WJ (September 1993). "Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment". The British Journal of Dermatology. 129 (3): 292–6. doi:10.1111/j.1365-2133.1993.tb11849.x. PMID 8286227. S2CID 22251719.
- Thiboutot DM, Cockerell CJ (August 2006). "iPLEDGE: A Report from the Front Lines of Dermatologic Practice". The Virtual Mentor. 8 (8): 524–8. doi:10.1001/virtualmentor.2006.8.8.pfor1-0608. PMID 23234692.
- Sladden MJ, Harman KE (September 2007). "What is the chance of a normal pregnancy in a woman whose fetus has been exposed to isotretinoin?". Archives of Dermatology. 143 (9): 1187–8. doi:10.1001/archderm.143.9.1187. PMID 17875883.
- Shin, Janet; Cheetham, T. Craig; Wong, Linda; Niu, Fang; Kass, Elizabeth; Yoshinaga, Monica A.; Sorel, Mike; McCombs, Jeffrey S.; Sidney, Stephen (December 2011). "The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system". Journal of the American Academy of Dermatology. 65 (6): 1117–1125. doi:10.1016/j.jaad.2010.09.017. PMID 21565419.
- Prevost N, English JC (October 2013). "Isotretinoin: update on controversial issues". Journal of Pediatric and Adolescent Gynecology. 26 (5): 290–3. doi:10.1016/j.jpag.2013.05.007. PMID 24147278.
- Robertson J, Polifka JE, Avner M, Chambers C, Delevan G, Koren G, Lavigne SV, Martinez LP, Miller RK, Carey JC (November 2005). "A survey of pregnant women using isotretinoin". Birth Defects Research. Part A, Clinical and Molecular Teratology. 73 (11): 881–7. doi:10.1002/bdra.20197. PMID 16228976.
Almost 1/4 of the women surveyed (24%; 8/34) did not recall having contraception counselling before starting their medications. Once therapy was initiated, 62% (21/34) recalled using a birth control method, but only 29% (6/21) recalled using 2 forms of birth control, as specified by the voluntary pregnancy prevention programs. Monthly pregnancy tests were not always conducted during treatment, as recalled by the surveyed women (56%; 19/34). As many as 24% (8/34) of the women surveyed recalled that they were not screened using 2 pregnancy tests before receiving a prescription, another recommendation of the programs. Only a small number of the women (30%; 6/20) in the United States recalled being enrolled in any manufacturers' voluntary pregnancy prevention survey. . . Results demonstrate that essential components of voluntary pregnancy prevention programs were not consistently followed, which resulted in fetal exposures.
- Leyden JJ, Del Rosso JQ, Baum EW (February 2014). "The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions". The Journal of Clinical and Aesthetic Dermatology. 7 (2 Suppl): S3–S21. PMC 3970835. PMID 24688620.
- Kovitwanichkanont T, Driscoll T (September 2018). "A comparative review of the isotretinoin pregnancy risk management programs across four continents". International Journal of Dermatology. 57 (9): 1035–1046. doi:10.1111/ijd.13950. PMID 29508918. S2CID 3726217.
- Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3) e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
- Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.
- Tirado Sánchez A, León Dorantes G (Nov–Dec 2005). "Erectile dysfunction during isotretinoin therapy". Actas Urologicas Espanolas. 29 (10): 974–6. doi:10.1016/s0210-4806(05)73379-9. PMID 16447596.
ncbi.nlm.nih.gov
- Layton A (May 2009). "The use of isotretinoin in acne". Dermato-Endocrinology. 1 (3): 162–9. doi:10.4161/derm.1.3.9364. PMC 2835909. PMID 20436884.
- Leyden JJ, Del Rosso JQ, Baum EW (February 2014). "The use of isotretinoin in the treatment of acne vulgaris: clinical considerations and future directions". The Journal of Clinical and Aesthetic Dermatology. 7 (2 Suppl): S3–S21. PMC 3970835. PMID 24688620.
- Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3) e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
researchgate.net (Global: 96th place; English: 89th place)
semanticscholar.org (Global: 15th place; English: 8th place)
api.semanticscholar.org
- Layton AM, Knaggs H, Taylor J, Cunliffe WJ (September 1993). "Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment". The British Journal of Dermatology. 129 (3): 292–6. doi:10.1111/j.1365-2133.1993.tb11849.x. PMID 8286227. S2CID 22251719.
- Kovitwanichkanont T, Driscoll T (September 2018). "A comparative review of the isotretinoin pregnancy risk management programs across four continents". International Journal of Dermatology. 57 (9): 1035–1046. doi:10.1111/ijd.13950. PMID 29508918. S2CID 3726217.
the-dermatologist.com (Global: low place; English: low place)
- "Isotretinoin Update | The Dermatologist". www.the-dermatologist.com.
- Life After iPLEDGE, The Dermatologist, September 4, 2008.
web.archive.org (Global: 1st place; English: 1st place)
- Research, Center for Drug Evaluation and (2021-10-12). "iPLEDGE Risk Evaluation and Mitigation Strategy (REMS)". FDA. Archived from the original on October 12, 2021.
- "FDA targets illegal online pharmacies in globally coordinated action". Food and Drug Administration. Archived from the original on 2017-02-17. Retrieved 2019-12-16.
- "RISK EVALUATION AND MITIGATION STRATEGY (REMS)". www.fda.gov. 2012. Archived from the original (PDF) on December 15, 2019. Retrieved 2019-07-03.
worldcat.org (Global: 4th place; English: 4th place)
search.worldcat.org
- Shah, Nidhi; Byrne, Morgan; Kirkorian, A. Yasmine (2021-09-01). "27483 Evaluating the economic burden of iPLEDGE on female patients". Journal of the American Academy of Dermatology. 85 (3): AB148. doi:10.1016/j.jaad.2021.06.606. ISSN 0190-9622.
- Mostaghimi, Arash; Joyce, Cara; Waul, Michael; Lu, Jessica; Xia, Fan Di; Charrow, Alexandra (2019-03-26). "Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era". PLOS ONE. 14 (3) e0210445. Bibcode:2019PLoSO..1410445C. doi:10.1371/journal.pone.0210445. ISSN 1932-6203. PMC 6435230. PMID 30913210. Material was copied from this source, which is available under a Creative Commons Attribution 4.0 International License.
- Turrion-Merino, Lucia; Urech-García-de-la-Vega, Marta; Miguel-Gomez, Laura; Harto-Castaño, Antonio; Jaen-Olasolo, Pedro (2015-11-01). "Severe Acne in Female-to-Male Transgender Patients". JAMA Dermatology. 151 (11): 1260–1261. doi:10.1001/jamadermatol.2015.0761. ISSN 2168-6068. PMID 25992965.